BEARINGPOINT
24.11.2022 13:16:34 CET | Business Wire | Press release
Management and technology consultancy BearingPoint’s latest study suggests mobility decisions will be very different by 2030. The study, “Destination 2030, Who’s in the driving seat for the future of mobility?” identified three trends that will drive mobility in the coming years:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221124005066/en/
Destination 2030 - who’s in the driving seat for the future of mobility? (Graphic: Business Wire)
1.) every journey will become a personalized experience
2.) climate neutrality will be non-negotiable – from the cradle to the grave
3.) users will consume services rather than own vehicles.
“It will be a radically different mobility ecosystem that will affect automotive manufacturers, transportation providers, and even energy suppliers as well as tech and insurance companies. What changes is how services are provided and consumed, and these industries must start preparing now. The growth of personalized mobility, mobility as a service and the push towards carbon-neutrality will all profoundly impact the way we think about travel. We’ll control our travel experiences in a new way, and this will impact our relationship with car brands, potentially weakening their ownership of us as customers,” said Dr. Stefan Penthin, global leader Automotive, Industrial Equipment & Manufacturing at BearingPoint.
Remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility
The study drew from BearingPoint’s internal research, the views of clients across all industry sectors and input from the consultancy’s sector and technology leaders. The study says remote work, energy crises, climate change and supply chain disruptions are profoundly changing the demand for mobility and the direction and pace of change.
“87% of the survey participants believe they will commute less frequently to work and 81% said they will take significantly fewer business trips compared to 2019, and if this trend continues, it will impact investment in infrastructure. The increased costs associated with developing new mobility infrastructure cannot be passed on entirely to the end user. Legislation may also need to be implemented to achieve the right infrastructure to support electric vehicles. Licensing and enforcement will shift focus from the individual to the provider,” said Andrew Montgomery, global leader Government and Public Sector at BearingPoint.
Three trends that will drive mobility in the coming years
The study sees every journey becoming a personalized experience. Public transportation will shift toward individual mobility, with schedules dictated by consumer needs, rather than predefined as with traditional public transportation. This will lead to more user-centric offerings, making traveling time more productive.
Climate neutrality will be non-negotiable, according to the study, which points to 80% of manufactured engines being green by 2030. Investment will increase in zero-impact modes and related infrastructure, particularly those that promote well-being, such as walking and cycling. And half of the participants (49%) say that they would sacrifice vehicle ownership to reduce their environmental footprint by 2030.
As users will consume services rather than own vehicles, they will switch to on-demand services rather than owning an underutilized vehicle. The services and software will be more important to the general consumer than the physical vehicle and brand, as software platforms will orchestrate the entire journey. 81% of participants point out that they will prefer to use one single app/platform for ordering and billing all their mobility-related services. The study also sees new entrants as constructors, not disruptors.
For more details, please read the full article here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005066/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
